Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated June 27, 2019, reports the resolutions passed at the 143rd Ordinary General Meeting of Shareholders. The filing covers the conclusion of the 142nd fiscal year (April 1, 2018 to March 31, 2019) and the election of new directors and approval of compensation plans.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms that the Consolidated and Unconsolidated Financial Statements for the 142nd fiscal year were reported to shareholders, but the numerical data is not included in this document.
Dividend: The year-end dividend was approved at 90 yen (JPY90.00) per share.
Material Changes and Resolutions
- Dividend Appropriation: The proposal to appropriate surplus for a 90 yen per share dividend was approved.
- Board Elections: Twelve Directors (non-Audit and Supervisory Committee) were elected, including nine re-elections and three new appointments (Constantine Saroukos, Jean-Luc Butel, Shiro Kuniya). Two new Directors were elected to the Audit and Supervisory Committee (Emiko Higashi, Michel Orsinger).
- Compensation Revisions:
- Stock compensation plans were revised for Directors (excluding Audit Committee and overseas non-External Directors) with a trust contribution cap of 4,500 million yen over three years.
- Stock compensation for Audit and Supervisory Committee Members was revised with a trust contribution cap of 200 million yen over three years.
- Bonuses totaling up to 730 million yen were approved for two specific Directors.
- Rejected Proposals: Shareholder proposals to amend the Articles of Incorporation for individual director compensation disclosure and to adopt a clawback clause were rejected.
Guidance, Outlook, and Risks
The filing text does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The document is strictly a notice of shareholder meeting resolutions.
Investor Verification Checklist
- Verify the exact financial performance figures (revenue, net income) for the 142nd fiscal year in the full Annual Report (Form 20-F) or the referenced Consolidated Financial Statements.
- Confirm the payment date and method for the 90 yen per share dividend.
- Review the specific terms of the new stock compensation trusts and bonus allocations approved for directors.
- Monitor the impact of the rejected shareholder proposals regarding transparency and clawback clauses on future governance.